heat-stable subunit Ebola vaccine

The heat-stable subunit Ebola vaccine is a recombinant protein-based vaccine candidate developed through a collaboration between **Soligenix**, the **University of Hawai'i at Manoa**, and **Hawaii Biotech**. The vaccine utilizes recombinant Ebola virus glycoprotein (GP) antigens to induce protective immunity. A distinguishing feature of this candidate is the integration of Soligenix's proprietary **ThermoVax** technology, which employs a lyophilization (freeze-drying) process to produce a thermostable formulation. This technology aims to eliminate the requirement for a continuous cold chain, allowing the vaccine to remain stable at temperatures up to 40 degrees Celsius. This addresses significant logistical challenges in distributing vaccines to outbreak-prone regions with limited refrigeration infrastructure.

Other names

recombinant protein subunit Ebola vaccineSoligenix Ebola vaccineThermoVax stabilized Ebola vaccineEBOV GP subunit vaccine